As of 2025-11-18, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -14.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 1,521.99 mil USD. TXG's TTM EBITDA according to its financial statements is -106.62 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 17.4x | 14.4x |
| Forward P/E multiples | 19.8x - 21.3x | 20.7x |
| Fair Price | (13.47) - (11.39) | (11.58) |
| Upside | -185.8% - -172.6% | -173.7% |
| Date | EV/EBITDA |
| 2025-11-17 | -14.27 |
| 2025-11-14 | -14.50 |
| 2025-11-13 | -15.03 |
| 2025-11-12 | -15.43 |
| 2025-11-11 | -15.31 |
| 2025-11-10 | -15.89 |
| 2025-11-07 | -13.75 |
| 2025-11-06 | -11.12 |
| 2025-11-05 | -11.69 |
| 2025-11-04 | -11.54 |
| 2025-11-03 | -11.94 |
| 2025-10-31 | -11.87 |
| 2025-10-30 | -10.47 |
| 2025-10-29 | -11.01 |
| 2025-10-28 | -11.52 |
| 2025-10-27 | -11.81 |
| 2025-10-24 | -12.02 |
| 2025-10-23 | -11.54 |
| 2025-10-22 | -10.26 |
| 2025-10-21 | -11.16 |
| 2025-10-20 | -11.29 |
| 2025-10-17 | -9.76 |
| 2025-10-16 | -10.40 |
| 2025-10-15 | -9.83 |
| 2025-10-14 | -9.42 |
| 2025-10-13 | -9.49 |
| 2025-10-10 | -9.34 |
| 2025-10-09 | -9.62 |
| 2025-10-08 | -10.04 |
| 2025-10-07 | -9.49 |
| 2025-10-06 | -10.70 |
| 2025-10-03 | -10.83 |
| 2025-10-02 | -10.32 |
| 2025-10-01 | -10.41 |
| 2025-09-30 | -9.59 |
| 2025-09-29 | -9.18 |
| 2025-09-26 | -9.63 |
| 2025-09-25 | -9.90 |
| 2025-09-24 | -10.02 |
| 2025-09-23 | -10.53 |
| 2025-09-22 | -11.17 |
| 2025-09-19 | -11.17 |
| 2025-09-18 | -11.44 |
| 2025-09-17 | -10.96 |
| 2025-09-16 | -11.27 |
| 2025-09-15 | -11.53 |
| 2025-09-12 | -10.70 |
| 2025-09-11 | -11.19 |
| 2025-09-10 | -10.64 |
| 2025-09-09 | -11.71 |